Optimum Dosing Strategies’s ID – ODS design allows integration with a variety of third-party systems, giving health care practitioners vital access to the data they need at the point of care. Click here to contact us for further details about integrating ID – ODS into the workflow with your institutions electronic medical record.
User Guide
Standardized data input format Do not edit column headers Each date and time line item and the corresponding cells in the same row must have an entry for each column, as shown in the template. ID – Subject ID Number. Time – Date and time of the event corresponding to the data input type. Formatting […]
... MoreRecharge
2012 – Farkas A, Successful target attainment of telavancin at elevated MICs: fact or fiction? 2012, Antimicrobial Agents and Chemotherapy, 56: 4560
MoreID-ODS 5.0: Enterprise level dose optimization…
ID-ODS 5.0 includes options for easy upload of enterprise ready data sets for users with access to advanced functionality. Utilize your available IT talent within your health care system to extract data into our standardized data format from your EMR and avoid the substantial cost of direct integration and the inconvenience of manual data entry!
MoreSee recent publication on ID – ODS!
A work published in March, 2024 in the journal Intensive Care Medicine focused on evaluating the clinical and economic impact of using ID-ODS in critically ill patients…
MoreInvest in precision dosing and ID – ODS…
We appreciate your interest in precision dosing and the system of ID – ODS, the next generation interactive dose optimization application. Contact us at [email protected] to discuss investment opportunities in ID – ODS…
MoreManuscripts and Letters
2012 – Farkas A, Successful target attainment of telavancin at elevated MICs: fact or fiction? 2012, Antimicrobial Agents and Chemotherapy, 56: 4560
MoreIDSA
2014 – Barry P.; Deck D.; Farkas A.; Pharmacokinetic modeling of linezolid dosing regimens for multidrug resistant tuberculosis
2013 – Farkas A, Rowin K; Pharmacodynamics of doripenem in critically ill patients: does race matter
MoreACCP
2012- Sussman R, Farkas A, Lee A, Evaluation of pharmacist managed vancomycin therapy compared to physician managed dosing in establishing timely and therapeutic vancomycin serum concentrations at a community hospital
2012 – Farkas A, Keren A, Hoffman C; Novel method to maximize levofloxacin pharmacodynamics for the treatment of systemic gram negative infections based on the population distribution of patient demographics at a community hospital
MoreECCMID
2014 – Farkas A, Daroczi G, Roberts J, Population Probability of Target Attainment of Colistin at Different Levels of Renal Function Against Pseudomonas aeruginosa and Acinetobacter baumanii in Europe
2014 – Farkas A, Daroczi G, Roberts J, Usage statistics of Individually Designed Optimum Dosing Strategies, a multi-model based online application to individualize antibiotic dosing in critically ill patients
MoreASM Microbe
2014 – Farkas A.; Saju S.; Gould P.; Kuriyilel J.; Villasurda P.; Roberts J.; Comparative evaluation of the performance of a population equation and two Bayesian methods to predict future Vancomycin concentrations .
2014 – Farkas A.; Villasurda P.; Feldfogel H.; Afroz S.; Evaluation Of The Safety And Efficacy Of Low Versus High Vancomycin Trough Levels For The Treatment Of Conditions Caused By Methicillin-Resistant Staphylococcus Aureus
More